Cancer drug developers Kite Pharma Inc and Bluebird Bio Inc said they would partner to develop and market a new class of T-cell therapies for HPV-associated cancers. T-cell receptors (TCRs) are a class of compounds that make it easier for the body’s immune cells to mainly identify and then destroy cancer cells. Human papilloma virus […]
Featured Posts
R&D/Pipelines Report 2022: Innovating to turn the tide - The world’s leading COVID-19 vaccine and therapeutic manufacturers continue to develop treatments for the waves of variants as well as life-changing therapies for disease areas outside the world of coronaviruses. The world’s efforts to combat the global pandemic continue to evolve, as does Coronavirus Disease 2019 as variants and subvariants constantly toss volleys of grenades at the battlefront lines.The newest HPV vaccine safely and effectively prevents at least four different kinds of cancer in the population recommended to receive it, according to a study in Pediatrics today. Gardasil 9, manufactured by Merck, protects against nine strains of the human papillomavirus, an infection transmitted through direct or indirect contact with the genitals of an […]
Germany-based Boehringer Ingelheim announced today positive results from a Phase III RE-VERSE AD clinical trial. The study shows that 5 grams of idarucizumab almost immediately reversed the anticoagulant effect of dabigatran (Pradaxa) in patients who needed it under emergency situations. Study results were also simultaneously published in The New England Journal of Medicine under the […]
SYDNEY, June 22, 2015 /PRNewswire/ — Benitec Biopharma (ASX: BLT; OTCPK: BTEBD) is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the Company’s proprietary ddRNAi technology. Entry into these areas have been facilitated by the commencement of a collaboration with UK-based stem cell therapeutics company, ReNeuron. The program […]
Amgen Inc said its drug met the main goal of improving overall survival in metastatic colorectal cancer patients who have not responded to chemotherapy. The late-stage study was testing the drug, Vectibix, in combination with best supportive care (BSC), compared with BSC alone. Patients who received 6 mg/kg of the drug every 14 days and […]
Effort With CDC to Collect, Analyze and Disseminate Much-Needed Sickle Cell Information ATLANTA, GA–(Marketwired – June 19, 2015) – Sickle cell disease (SCD), estimated to affect nearly 100,000 Americans, is the most common inherited blood disorder in the United States and the estimated cost of care for sickle cell disease is approximately $1.1 billion dollars […]
PARIS, June 19, 2015 /PRNewswire/ — MedDay, a biotechnology company focused on the treatment of nervous system disorders, reports additional positive data from its pivotal Phase III clinical trial, MS-SPI, with MD1003, a highly-concentrated pharmaceutical grade biotin, in patients with Progressive Multiple Sclerosis. The data, to be announced on Saturday 20th June at The 1st […]
German drugs and chemicals group Bayer plans to invest 4 billion euros ($4.54 billion) in research and development this year, its chief executive told Germany’s Bild newspaper. “That is more than ever before. The development of our new blood thinner Xarelto alone cost 2.2 billion euros,” Marijn Dekkers. Aspirin maker Bayer raised its research and […]
Amgen (AMGN), headquartered in Thousand Oaks, Calif., announced yesterday that its Phase III study of Vectibix (panitumumab) had met its primary endpoint in the treatment of chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC). The study was designed to determine the survival benefit of Vectibix and best supportive care (BSC) in comparison to BSC […]
German drugs and chemicals group Bayer plans to invest 4 billion euros ($4.54 billion) in research and development this year, its chief executive told Germany’s Bild newspaper. “That is more than ever before. The development of our new blood thinner Xarelto alone cost 2.2 billion euros,” Marijn Dekkers. Aspirin maker Bayer raised its research and […]